Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APD356-lorcaserin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| APD356-lorcaserin hydrochloride | DRUG | - |
| Placebo | DRUG | - |
APD356-lorcaserin is an investigational small molecule being studied for smoking cessation. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is being evaluated to help people stop smoking, though it remains investigational and is not yet available as a treatment.
APD356-lorcaserin is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. Pfizer is conducting clinical research on this drug for smoking cessation, and it is currently in Phase 2 development.
APD356-lorcaserin is in Phase 2 clinical development for smoking cessation. It is an investigational drug and has not been approved by the FDA. The drug is still being studied in clinical trials to evaluate its safety and effectiveness.
APD356-lorcaserin has one completed Phase 2 clinical trial with the identifier NCT02044874, titled "A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation." This trial enrolled 603 participants and was an uncontrolled study, meaning there was no control group.
APD356-lorcaserin is the same drug as lorcaserin, as indicated by the trial title which refers to lorcaserin hydrochloride. The drug is being developed by Pfizer for smoking cessation and is currently in Phase 2 clinical development.